JP2011515397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515397A5 JP2011515397A5 JP2011500801A JP2011500801A JP2011515397A5 JP 2011515397 A5 JP2011515397 A5 JP 2011515397A5 JP 2011500801 A JP2011500801 A JP 2011500801A JP 2011500801 A JP2011500801 A JP 2011500801A JP 2011515397 A5 JP2011515397 A5 JP 2011515397A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- lower alkyl
- hydrogen
- optionally substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- -1 heterocyclyloxyalkyl Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000001302 tertiary amino group Chemical group 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000010962 ALK-positive anaplastic large cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 1
- ZWIJMWCYBYYPLU-UHFFFAOYSA-N NNC(=O)C(N)=N Chemical compound NNC(=O)C(N)=N ZWIJMWCYBYYPLU-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005124 aminocycloalkyl group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 125000005335 azido alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 0 C[C@@](C*)NC(C=CNC1O)=C1c1nc(C(*)C(C(CN2*)=C3*)C2=O)c3[n]1 Chemical compound C[C@@](C*)NC(C=CNC1O)=C1c1nc(C(*)C(C(CN2*)=C3*)C2=O)c3[n]1 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3803208P | 2008-03-19 | 2008-03-19 | |
| US61/038,032 | 2008-03-19 | ||
| PCT/US2009/001691 WO2009117097A1 (en) | 2008-03-19 | 2009-03-18 | Novel tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013006922A Division JP2013082744A (ja) | 2008-03-19 | 2013-01-18 | 新規チロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011515397A JP2011515397A (ja) | 2011-05-19 |
| JP2011515397A5 true JP2011515397A5 (enExample) | 2012-05-10 |
| JP5628145B2 JP5628145B2 (ja) | 2014-11-19 |
Family
ID=40814009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011500801A Expired - Fee Related JP5628145B2 (ja) | 2008-03-19 | 2009-03-18 | 新規チロシンキナーゼ阻害剤 |
| JP2013006922A Pending JP2013082744A (ja) | 2008-03-19 | 2013-01-18 | 新規チロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013006922A Pending JP2013082744A (ja) | 2008-03-19 | 2013-01-18 | 新規チロシンキナーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8815906B2 (enExample) |
| EP (2) | EP2966076A1 (enExample) |
| JP (2) | JP5628145B2 (enExample) |
| CN (1) | CN102036990B (enExample) |
| AU (1) | AU2009226153B2 (enExample) |
| CA (1) | CA2718872C (enExample) |
| DK (1) | DK2262807T3 (enExample) |
| MX (1) | MX2010010272A (enExample) |
| WO (1) | WO2009117097A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2262807T3 (en) * | 2008-03-19 | 2015-11-30 | Chembridge Corp | NOVEL tyrosine kinase inhibitors |
| US9249147B2 (en) * | 2008-03-19 | 2016-02-02 | Chembridge Corporation | Tyrosine kinase inhibitors |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| RS58326B1 (sr) | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
| WO2013074518A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| BR112014026266A2 (pt) | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| BR112014026305A2 (pt) * | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| CN109970742A (zh) | 2012-07-04 | 2019-07-05 | 理森制药股份公司 | 选择性PI3Kδ抑制剂 |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| CN104109168B (zh) * | 2013-04-20 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
| JP6562908B2 (ja) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびその類似体 |
| US10005739B2 (en) | 2013-10-23 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| HRP20200662T1 (hr) * | 2014-02-04 | 2020-10-02 | Astellas Pharma Inc. | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak |
| WO2015161152A1 (en) * | 2014-04-17 | 2015-10-22 | Amgen Inc. | Polymorphic forms and co-crystals of a c-met inhibitor |
| EP3154589A1 (en) | 2014-06-13 | 2017-04-19 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| WO2016142835A1 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | Therapeutic cyclic compounds as immunomodulators |
| KR20180012853A (ko) | 2015-06-16 | 2018-02-06 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도 |
| HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
| CN108602890A (zh) | 2015-12-11 | 2018-09-28 | 瑞泽恩制药公司 | 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CA3106239A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN116096715A (zh) | 2020-07-06 | 2023-05-09 | 泰科根公司 | 用于精神障碍或精神增强的有益苯并噻吩组合物 |
| CA3187217A1 (en) | 2020-08-06 | 2022-02-10 | Matthew BAGGOTT | 2-aminoindane compounds for mental disorders or enhancement |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| EP0600830A1 (de) * | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Substituierte Derivate von Diaminophthalimid als Protein-Tyrosin-Kinase-Hemmer |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO2004063151A2 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Novel tyrosine kinase inhibitors |
| US20060211724A1 (en) | 2003-04-28 | 2006-09-21 | Verschueren Gaston W | Hiv integrase inhibitors |
| AU2004259012C1 (en) * | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20060235013A1 (en) * | 2005-04-14 | 2006-10-19 | Guy Georges | Tricyclic azole derivatives |
| US20090005396A1 (en) * | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
| US20080062003A1 (en) * | 2006-08-07 | 2008-03-13 | Christian Paetz | Wireless controllable power control device molded into a power cable |
| US8063225B2 (en) * | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| WO2008022747A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| DK2262807T3 (en) * | 2008-03-19 | 2015-11-30 | Chembridge Corp | NOVEL tyrosine kinase inhibitors |
-
2009
- 2009-03-18 DK DK09721981.0T patent/DK2262807T3/en active
- 2009-03-18 AU AU2009226153A patent/AU2009226153B2/en not_active Ceased
- 2009-03-18 US US12/922,891 patent/US8815906B2/en not_active Expired - Fee Related
- 2009-03-18 CN CN200980118256.XA patent/CN102036990B/zh not_active Expired - Fee Related
- 2009-03-18 EP EP15177176.3A patent/EP2966076A1/en not_active Withdrawn
- 2009-03-18 WO PCT/US2009/001691 patent/WO2009117097A1/en not_active Ceased
- 2009-03-18 EP EP09721981.0A patent/EP2262807B1/en not_active Not-in-force
- 2009-03-18 JP JP2011500801A patent/JP5628145B2/ja not_active Expired - Fee Related
- 2009-03-18 CA CA2718872A patent/CA2718872C/en not_active Expired - Fee Related
- 2009-03-18 MX MX2010010272A patent/MX2010010272A/es active IP Right Grant
-
2013
- 2013-01-18 JP JP2013006922A patent/JP2013082744A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015207757B2 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| JP2010241830A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| RU2015125307A (ru) | Комбинированная терапия | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JP2016528246A5 (enExample) | ||
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP2008528468A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
| JP2010502651A5 (enExample) | ||
| CA3094449A1 (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2015524472A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| JP2020514409A5 (enExample) | ||
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| JP2009536620A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2012097115A5 (enExample) |